{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:01:53Z","timestamp":1787022113111,"version":"build-2736575974"},"reference-count":58,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>\n                    The resistance and the birth of new intrinsic and multidrug-resistant pathogenic species like\n                    <jats:italic>C<\/jats:italic>\n                    .\n                    <jats:italic>auris<\/jats:italic>\n                    is creating great concern in the antifungal world. Given the limited drug arsenal and the lack of effectiveness of the available compounds, there is an urgent need for innovative approaches. The murine mAb 2G8 was humanized and engineered\n                    <jats:italic>in silico<\/jats:italic>\n                    to develop a single-chain fragment variable (hscFv) antibody against \u03b2-1,3-glucans which was then expressed in\n                    <jats:italic>E<\/jats:italic>\n                    .\n                    <jats:italic>coli<\/jats:italic>\n                    . Among the recombinant proteins developed, a soluble candidate with high stability and affinity was obtained. This selected protein is VL-linker-VH oriented, and it is characterized by the presence of two ubiquitin monomers at the N-terminus and a His tag at the C-terminus. This construct, Ub\n                    <jats:sub>2<\/jats:sub>\n                    -hscFv-His, guaranteed stability, solubility, efficient purification and satisfactory recovery of the recombinant product. HscFv can bind \u03b2-1,3-glucans both as coated antigens and on\n                    <jats:italic>C<\/jats:italic>\n                    .\n                    <jats:italic>auris<\/jats:italic>\n                    and\n                    <jats:italic>C<\/jats:italic>\n                    .\n                    <jats:italic>albicans<\/jats:italic>\n                    cells similarly to its murine parental and showed long stability and retention of binding ability when stored at 4\u00b0, -20\u00b0 and -80\u00b0 C. Furthermore, it was efficient in enhancing the antifungal activity of drugs caspofungin and amphotericin B against\n                    <jats:italic>C<\/jats:italic>\n                    .\n                    <jats:italic>auris<\/jats:italic>\n                    . The use of biological drugs as antifungals is limited; here we present a promising hscFv which has the potential to be useful in combination with currently available antifungal drugs.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0276786","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T13:42:08Z","timestamp":1667223728000},"page":"e0276786","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["Development and in vitro characterization of a humanized scFv against fungal infections"],"prefix":"10.1371","volume":"17","author":[{"given":"Tomas","family":"Di Mambro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9053-1558","authenticated-orcid":true,"given":"Tania","family":"Vanzolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9352-7319","authenticated-orcid":true,"given":"Marzia","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Crinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Canonico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Tasini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5206-6296","authenticated-orcid":true,"given":"Michele","family":"Menotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6456-6626","authenticated-orcid":true,"given":"Mauro","family":"Magnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,10,31]]},"reference":[{"key":"pone.0276786.ref001","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev-bioeng-071114-040733","article-title":"Advances in Antibody Design","volume":"17","author":"KE Tiller","year":"2015","journal-title":"Annu Rev Biomed Eng"},{"key":"pone.0276786.ref002","first-page":"78","article-title":"Muromonab-CD3 (Orthoclone OKT3): the first monoclonal antibody approved for therapeutic use","volume":"77","author":"C Emmons","year":"1987","journal-title":"Iowa Med J Iowa Med Soc"},{"key":"pone.0276786.ref003","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0300-483X(95)03123-W","article-title":"Side-effects of a monoclonal antibody, muromonab CD3\/orthoclone OKT3: bibliographic review","volume":"105","author":"C Sgro","year":"1995","journal-title":"Toxicology"},{"key":"pone.0276786.ref004","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2147\/tcrm.2007.3.2.259","article-title":"Natalizumab: A new treatment for relapsing remitting multiple sclerosis","volume":"3","author":"M Hutchinson","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"pone.0276786.ref005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"R-M Lu","year":"2020","journal-title":"J Biomed Sci"},{"key":"pone.0276786.ref006","doi-asserted-by":"crossref","first-page":"980250","DOI":"10.1155\/2012\/980250","article-title":"scFv antibody: principles and clinical application","volume":"2012","author":"ZA Ahmad","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"pone.0276786.ref007","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4161\/mabs.2.1.10786","article-title":"Antibody fragments","volume":"2","author":"AL Nelson","year":"2010","journal-title":"mAbs"},{"key":"pone.0276786.ref008","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jconrel.2020.08.021","article-title":"Antibody and antibody fragments for cancer immunotherapy","volume":"328","author":"W Chen","year":"2020","journal-title":"J Control Release Off J Control Release Soc"},{"key":"pone.0276786.ref009","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/j.drudis.2018.06.003","article-title":"Therapeutic application of antibody fragments in autoimmune diseases: current state and prospects","volume":"23","author":"JC Fernandes","year":"2018","journal-title":"Drug Discov Today"},{"key":"pone.0276786.ref010","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejbt.2017.07.003","article-title":"Application of a single-chain fragment variable (scFv) antibody for the confirmatory diagnosis of hydatid disease in non-endemic areas","volume":"29","author":"X Xu","year":"2017","journal-title":"Electron J Biotechnol"},{"key":"pone.0276786.ref011","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","article-title":"Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty","volume":"330","author":"EPIC Investigators","year":"1994","journal-title":"N Engl J Med"},{"key":"pone.0276786.ref012","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/MPH.0b013e3181cb49a8","article-title":"Successful treatment of life-threatening Candida peritonitis in a child with abdominal non-Hodgkin lymphoma using Efungumab and amphotericin B colloid dispersion","volume":"32","author":"Z Krenova","year":"2010","journal-title":"J Pediatr Hematol Oncol"},{"key":"pone.0276786.ref013","first-page":"e23","article-title":"Treatment of a critically ill child with disseminated Candida glabrata with a recombinant human antibody specific for fungal heat shock protein 90 and liposomal amphotericin B, caspofungin, and voriconazole","volume":"9","author":"A Sutherland","year":"2008","journal-title":"Pediatr Crit Care Med J Soc Crit Care Med World Fed Pediatr Intensive Crit Care Soc"},{"key":"pone.0276786.ref014","volume-title":"Eur. Med. Agency","author":"EMA","year":"2022"},{"key":"pone.0276786.ref015","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1084\/jem.20050749","article-title":"A novel glyco-conjugate vaccine against fungal pathogens","volume":"202","author":"A Torosantucci","year":"2005","journal-title":"J Exp Med"},{"key":"pone.0276786.ref016","doi-asserted-by":"crossref","first-page":"5085","DOI":"10.1128\/IAI.00278-07","article-title":"An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo","volume":"75","author":"A Rachini","year":"2007","journal-title":"Infect Immun"},{"key":"pone.0276786.ref017","doi-asserted-by":"crossref","first-page":"e5392","DOI":"10.1371\/journal.pone.0005392","article-title":"Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence","volume":"4","author":"A Torosantucci","year":"2009","journal-title":"PloS One"},{"key":"pone.0276786.ref018","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3390\/ijms23010545","article-title":"Multitalented Synthetic Antimicrobial Peptides and Their Antibacterial, Antifungal and Antiviral Mechanisms","volume":"23","author":"T Vanzolini","year":"2022","journal-title":"Int J Mol Sci"},{"key":"pone.0276786.ref019","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2014.00063","article-title":"Fusion tags for protein solubility, purification and immunogenicity in Escherichia coli: the novel Fh8 system","volume":"5","author":"S Costa","year":"2014","journal-title":"Front. Microbiol."},{"key":"pone.0276786.ref020","first-page":"1084-9521(21)00289\u20135","article-title":"Fast friends\u2014Ubiquitin-like modifiers as engineered fusion partners","author":"E Asimaki","year":"2021","journal-title":"Semin Cell Dev Biol S"},{"key":"pone.0276786.ref021","article-title":"Enhanced Production of Soluble Recombinant Proteins With an In Situ-Removable Fusion Partner in a Cell-Free Synthesis System","author":"D Kasi","year":"2017","journal-title":"Biotechnol J."},{"key":"pone.0276786.ref022","author":"M Murby","year":"1995","journal-title":"ARTICLE NO. 0018 REVIEW Upstream Strategies to Minimize Proteolytic Degradation upon Recombinant Production in Escherichia coli"},{"key":"pone.0276786.ref023","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.pep.2007.04.018","article-title":"High-level expression of the recombinant hybrid peptide cecropinA(1\u20138)-magainin2(1\u201312) with an ubiquitin fusion partner in Escherichia coli","volume":"55","author":"X Xu","year":"2007","journal-title":"Protein Expr Purif"},{"key":"pone.0276786.ref024","doi-asserted-by":"crossref","first-page":"19500","DOI":"10.1038\/s41598-021-98659-5","article-title":"A new humanized antibody is effective against pathogenic fungi in vitro","volume":"11","author":"T Di Mambro","year":"2021","journal-title":"Sci Rep"},{"key":"pone.0276786.ref025","unstructured":"SIB Swiss Institute of Bioinformatics | Expasy. https:\/\/www.expasy.org\/. Accessed 17 Jan 2021"},{"key":"pone.0276786.ref026","unstructured":"IgBlast tool. https:\/\/www.ncbi.nlm.nih.gov\/igblast\/. Accessed 17 Jan 2021"},{"key":"pone.0276786.ref027","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/j.molimm.2008.01.016","article-title":"Humanization of a highly stable single-chain antibody by structure-based antigen-binding site grafting","volume":"45","author":"ME Villani","year":"2008","journal-title":"Mol Immunol"},{"key":"pone.0276786.ref028","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/protein\/gzq092","article-title":"Humanization strategies for an anti-idiotypic antibody mimicking HIV-1 gp41","volume":"23","author":"A Mader","year":"2010","journal-title":"Protein Eng Des Sel PEDS"},{"key":"pone.0276786.ref029","author":"Bank RPD RCSB PDB","year":"2022","journal-title":"Homepage"},{"key":"pone.0276786.ref030","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1074\/jbc.M706190200","article-title":"Thermodynamic consequences of mutations in vernier zone residues of a humanized anti-human epidermal growth factor receptor murine antibody, 528","volume":"283","author":"K Makabe","year":"2008","journal-title":"J Biol Chem"},{"key":"pone.0276786.ref031","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/jms.1700","article-title":"Structural characterization of intact antibodies by high-resolution LTQ Orbitrap mass spectrometry","volume":"45","author":"J Zhang","year":"2010","journal-title":"J Mass Spectrom"},{"key":"pone.0276786.ref032","doi-asserted-by":"crossref","first-page":"e1001105","DOI":"10.1371\/journal.pbio.1001105","article-title":"Hyphal Development in Candida albicans Requires Two Temporally Linked Changes in Promoter Chromatin for Initiation and Maintenance","volume":"9","author":"Y Lu","year":"2011","journal-title":"PLOS Biol"},{"key":"pone.0276786.ref033","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/prot.22502","article-title":"Structural understanding of stabilization patterns in engineered bispecific Ig-like antibody molecules","volume":"77","author":"JL Jordan","year":"2009","journal-title":"Proteins"},{"key":"pone.0276786.ref034","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/prot.24522","article-title":"Structural evidence for a constrained conformation of short CDR-L3 in antibodies","volume":"82","author":"A Teplyakov","year":"2014","journal-title":"Proteins"},{"key":"pone.0276786.ref035","doi-asserted-by":"crossref","first-page":"6049","DOI":"10.1073\/pnas.1303682110","article-title":"Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody","volume":"110","author":"L Scharf","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pone.0276786.ref036","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1182\/blood-2012-01-401620","article-title":"Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model","volume":"119","author":"I Hilden","year":"2012","journal-title":"Blood"},{"key":"pone.0276786.ref037","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1038\/ncomms4139","article-title":"Two potential therapeutic antibodies bind to a peptide segment of membrane-bound IgE in different conformations","volume":"5","author":"H-M Chu","year":"2014","journal-title":"Nat Commun"},{"key":"pone.0276786.ref038","doi-asserted-by":"crossref","first-page":"8209","DOI":"10.1073\/pnas.1404653111","article-title":"Mechanism for neutralizing activity by the anti-CMV gH\/gL monoclonal antibody MSL-109","volume":"111","author":"AE Fouts","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pone.0276786.ref039","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0022-2836(92)91010-M","article-title":"Antibody framework residues affecting the conformation of the hypervariable loops","volume":"224","author":"J Foote","year":"1992","journal-title":"J Mol Biol"},{"key":"pone.0276786.ref040","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.3389\/fmicb.2020.01927","article-title":"Solubility, Stability, and Avidity of Recombinant Antibody Fragments Expressed in Microorganisms","volume":"11","author":"TH Kang","year":"2020","journal-title":"Front Microbiol"},{"key":"pone.0276786.ref041","doi-asserted-by":"crossref","first-page":"697876","DOI":"10.3389\/fcimb.2021.697876","article-title":"Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy","volume":"11","author":"KDR Roth","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"pone.0276786.ref042","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12934-019-1053-9","article-title":"Evaluation of scFv protein recovery from E. coli by in vitro refolding and mild solubilization process","volume":"18","author":"A Sarker","year":"2019","journal-title":"Microb Cell Factories"},{"key":"pone.0276786.ref043","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.mimet.2015.08.017","article-title":"Enhancing recombinant protein solubility with ubiquitin-like small archeal modifying protein fusion partners","volume":"118","author":"S Varga","year":"2015","journal-title":"J Microbiol Methods"},{"key":"pone.0276786.ref044","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1073\/pnas.86.8.2540","article-title":"Ubiquitin fusion augments the yield of cloned gene products in Escherichia coli","volume":"86","author":"TR Butt","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pone.0276786.ref045","doi-asserted-by":"crossref","first-page":"25381","DOI":"10.1016\/S0021-9258(18)47260-2","article-title":"Protein expression using cotranslational fusion and cleavage of ubiquitin. Mutagenesis of the glutathione-binding site of human Pi class glutathione S-transferase","volume":"269","author":"RT Baker","year":"1994","journal-title":"J Biol Chem"},{"key":"pone.0276786.ref046","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1021\/bp970040f","article-title":"Ubiquitin fusion technology: bioprocessing of peptides","volume":"13","author":"A Pilon","year":"1997","journal-title":"Biotechnol Prog"},{"key":"pone.0276786.ref047","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.3390\/ijms10093811","article-title":"Variations in IC50 Values with Purity of Mushroom Tyrosinase","volume":"10","author":"E Neeley","year":"2009","journal-title":"Int J Mol Sci"},{"key":"pone.0276786.ref048","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41598-020-80746-8","article-title":"Generation and functional characterization of a single-chain variable fragment (scFv) of the anti-FGF2 3F12E7 monoclonal antibody","volume":"11","author":"RB de Aguiar","year":"2021","journal-title":"Sci Rep"},{"key":"pone.0276786.ref049","article-title":"Emerging Fungal Infections: New Patients, New Patterns, and New Pathogens","author":"DZP Friedman","year":"2019","journal-title":"J Fungi Basel Switz"},{"key":"pone.0276786.ref050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/mmy\/myy054","article-title":"Candida auris: The recent emergence of a multidrug-resistant fungal pathogen","volume":"57","author":"K Forsberg","year":"2019","journal-title":"Med Mycol"},{"key":"pone.0276786.ref051","doi-asserted-by":"crossref","first-page":"165rv13","DOI":"10.1126\/scitranslmed.3004404","article-title":"Hidden Killers: Human Fungal Infections","volume":"4","author":"GD Brown","year":"2012","journal-title":"Sci Transl Med"},{"key":"pone.0276786.ref052","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.idc.2021.03.001","article-title":"Recent Trends in the Epidemiology of Fungal Infections","volume":"35","author":"EE Seagle","year":"2021","journal-title":"Infect Dis Clin North Am"},{"key":"pone.0276786.ref053","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jiph.2021.11.014","article-title":"A 20-year retrospective clinical analysis of Candida infections in tertiary centre: Single-center experience.","volume":"15","author":"Alshehri BA Muzaheed null","year":"2022","journal-title":"J Infect Public Health"},{"key":"pone.0276786.ref054","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1128\/AAC.47.7.2208-2216.2003","article-title":"Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90","volume":"47","author":"RC Matthews","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0276786.ref055","doi-asserted-by":"crossref","first-page":"e1007892","DOI":"10.1371\/journal.pgen.1007892","article-title":"Exposure of Candida albicans \u03b2 (1,3)-glucan is promoted by activation of the Cek1 pathway","volume":"15","author":"T Chen","year":"2019","journal-title":"PLoS Genet"},{"key":"pone.0276786.ref056","doi-asserted-by":"crossref","first-page":"e1003446","DOI":"10.1371\/journal.ppat.1003446","article-title":"Bruton\u2019s Tyrosine Kinase (BTK) and Vav1 Contribute to Dectin1-Dependent Phagocytosis of Candida albicans in Macrophages","volume":"9","author":"K Strijbis","year":"2013","journal-title":"PLoS Pathog"},{"key":"pone.0276786.ref057","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3390\/microorganisms9040807","article-title":"Candida auris: Epidemiology, Diagnosis, Pathogenesis, Antifungal Susceptibility, and Infection Control Measures to Combat the Spread of Infections in Healthcare Facilities","volume":"9","author":"S Ahmad","year":"2021","journal-title":"Microorganisms"},{"key":"pone.0276786.ref058","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/myc.12904","article-title":"Candida auris\u2014the growing menace to global health","volume":"62","author":"SA Lone","year":"2019","journal-title":"Mycoses"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0276786","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T16:14:19Z","timestamp":1701274459000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0276786"}},"subtitle":[],"editor":[{"given":"Israel","family":"Silman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,10,31]]},"references-count":58,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0276786","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,31]]}}}